<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388388</url>
  </required_header>
  <id_info>
    <org_study_id>CPC030</org_study_id>
    <nct_id>NCT00388388</nct_id>
  </id_info>
  <brief_title>Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects</brief_title>
  <official_title>Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Frosst Canada Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, parallel group, two-centre pilot study will test the
      hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis
      of pre-hypertension and pre-diabetes will have regression or reduced progression of
      hypertension-associated changes in their resistance arteries if their blood pressure is
      controlled for 6 months with losartan, whereas similar subjects whose blood pressure is
      equally well controlled using hydrochlorothiazide will have significantly less improvement of
      the changes in their resistance arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, parallel group, two-centre pilot study will test the
      hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis
      of pre-hypertension and pre-diabetes will have regression or reduced progression of
      hypertension-associated changes in their resistance arteries if their blood pressure is
      controlled for 6 months with losartan, whereas similar subjects whose blood pressure is
      equally well controlled using hydrochlorothiazide will have significantly less improvement of
      the changes in their resistance arteries.

      The study will be conducted by Dr. Ernesto Schiffrin at the Cardiovascular Prevention Center,
      Sir Mortimer B. Davis Jewish General Hospital, McGill University, in Montreal, in association
      with a co-investigator at a second site, Dr. Rhian M. Touyz at the Ottawa General Hospital's
      Hypertension Clinic at the Riverside Campus and Kidney Research Center (University of
      Ottawa/Ottawa Health Research Institute). Over the past 15 years, Dr. Schiffrin has developed
      the gluteal subcutaneous biopsy methodology to be applied in the study. The technique has
      been practiced for many years (15 years) by Dr. Schiffrin, who more recently has collaborated
      with Dr. Touyz who used the technique together with Dr. Schiffrin before moving to Ottawa in
      2005. In addition, stiffness of aorta (carotid-femoral pulse wave velocity) and
      endothelium-dependent hyperemic responses will be evaluated. Dr. Schiffrin and Dr. Touyz will
      be responsible for patient recruitment, data collection and analysis, and maintenance of
      study charts and patient records. Merck-Frosst Canada Ltd (MFCL) will be responsible for the
      study budget and the supply of medication.

      The study subjects (men or women, 25 to 70 years of age) will be divided into two groups.
      Individuals with pre-hypertension (blood pressure = 120-139/85-90 mmHg) will be
      double-blindly allocated to either losartan or hydrochlorothiazide therapy respectively in
      groups 1 and 2. Study subjects will be assessed for their compatibility with inclusion and
      exclusion criteria, and subjects meeting the criteria will undergo baseline biopsies of
      gluteal subcutaneous resistance vessels. In addition, stiffness of aorta (carotid-femoral
      pulse wave velocity) and finger endothelium-dependent hyperemic responses will be evaluated.
      Subjects in each treatment group will receive antihypertensive therapy for 6 months, to
      control their blood pressure to 100-120/70-80 mmHg, and then have repeat gluteal biopsies,
      aortic stiffness and endothelial function measurements. The media/lumen ratio of resistance
      arteries 150-300 um in lumen diameter in the biopsied tissues will be determined. Previous
      work (1-3) has shown this parameter to be a useful marker of hypertensive vascular disease
      which may be modified by treatment with antihypertensive agents, particularly blockers of the
      renin-angiotensin system.

      Subjects will give informed consent, and be medically assessed to determine whether they
      satisfy the inclusion and exclusion criteria. Eligible subjects will have a sitting systolic
      blood pressure (SiSBP) 120-139 mmHg, and be otherwise in good health. Eligible subjects will
      have a gluteal biopsy, and then be randomized to treatment group 1 or group 2 for 6 months.

      For study purposes, SiSBP will be defined as the average of three consecutive valid readings,
      taken at one-minute intervals after five minutes of repose.

      Thirty subjects who satisfy the study criteria will be randomized to receive once daily
      therapy with either losartan 50 mg or hydrochlorothiazide 12.5 mg. Subjects will take study
      medication once daily between 06:30 and 11:00, and be followed up in morning clinic visits,
      scheduled between 06:30 and 11:00. Subjects will be instructed not to take their medication
      on the morning of clinic visits until after the clinic evaluations have been completed.
      During the 6 months of treatment, subjects will have their &quot;trough&quot; blood pressure, heart
      rate (HR) and body weight measured at every clinic visit. At visits where laboratory safety
      tests will be done, subjects will be asked to come fasting.

      All subjects will be force-titrated to losartan 100mg daily or hydrochlorothiazide 25 mg
      daily. However, if they develop dizziness and/or SiBPs below 100/70 mmHg, the dose may be
      down-titrated back to 50 mg losartan or 12.5 mg hydrochlorothiazide.

      If any subjects develops SiBPs &gt; 139/90 mmHg, open label amlodipine will be give to maintain
      SiBP &lt; 139/90 mmHg, attempting however to reach the goal of SiSBP &lt; 120 mmHg. Amlodipine will
      be started at a dose of 2.5mg daily and up-titrated every 4 weeks to 5 mg daily and then to
      10 mg daily. As long as SiBP &lt; 139/90 mmHg, subjects will not be discontinued from the study.
      Subjects whose hypertension is not adequately controlled (SiBP &gt; 139/90 mmHg) with addition
      of amlodipine up-titrated to 10 mg daily, however, will be discontinued from the study.

      Laboratory safety tests will be done at Weeks 4, 12, 24 of double-blind therapy (Visits 6, 8
      and 9). An ECG will be repeated at the end of the study (Week 24).

      The study will start at the end of 2006, last approximately 1 year. Recruitment should be
      completed within 6-9 months. Duration of other periods has been specified briefly above
      within the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Few subjects recruited, sponsor withdrew support.
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pre-hypertension</condition>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan, hydrochlorothiazide</intervention_name>
    <description>Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Cozaar, Apo-hydro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prehypertensive prediabetic subjects (25-70 years old) defined as otherwise normal
             subjects with a mean SiSBP of 120-139 mmHg and fasting blood glucose of 6.1-6.9 mmol/L
             or impaired glucose tolerance on oral glucose tolerance test (OGTT) at screening and
             after two weeks of placebo therapy (Week -2)

        Exclusion Criteria:

          -  Hypertension or clinically significant renal disease

          -  Cerebrovascular accident within the past year, or current transient ischemic attacks

          -  Myocardial infarction within the past year; percutaneous coronary angioplasty or
             coronary artery bypass surgery within last 6 months

          -  Clinically significant AV conduction disturbances and/or arrhythmias (e.g. second- or
             third-degree AV block; sick-sinus syndrome or clinically significant bradycardia-
             resting heart rate &lt; 45 beats/minute), tachyarrhythmias; clinically significant
             arrhythmias, presence of accessory bypass tract (e.g. Wolff-Parkinson-White syndrome)

          -  Angina pectoris

          -  Current or prior history of heart failure or known left ventricular ejection fraction
             &lt;40%

          -  History of unexplained syncope or known syncopal disorder (e.g., Stokes-Adams
             Syndrome)

          -  Known history of hemodynamically significant obstructive valvular disease or
             hypertrophic cardiomyopathy

          -  Use of agents that may cause alteration of blood pressure is prohibited. This includes
             nitrates, or alpha or beta-blockers. Calcium channel blockers are allowed as second
             line therapy if hypertension develops during the study Major psychotropic agents and
             antidepressants are not permitted

          -  Cimetidine is not permitted (famotidine and ranitidine and proton pump inhibitors are
             allowed).

          -  NSAIDs are permitted if taken on a stable regimen. Aspirin in small doses (&lt; 1 g/day)
             as cardioprotective agent and acetaminophen are permitted

          -  Oral or inhaled steroids, ACTH, immunosuppressants or lithium are not allowed

          -  Serum creatinine concentration &gt;200 Î¼mol/L (adjusted for age and weight)

          -  Urine dipstick or microscopic findings suggestive of significant renal or other
             disease.

          -  Hematuria should be evaluated, the etiology established/documented, and treatment
             rendered as appropriate prior to entry

          -  Off-treatment serum potassium concentration &gt;5.5 mmol/L or &lt;3.5 mmol/L

          -  AST (SGOT) or ALT (SGPT) &gt;2 x normal upper limit

          -  Clinically significant laboratory values outside of the established normal range
             including but not limited to the following parameters: hemoglobin, platelet count or
             white blood cell count

          -  Known hypersensitivity or contraindication to losartan or thiazide diuretics

          -  History of clinically important malabsorption or gastrointestinal resection

          -  Current urinary tract infection

          -  Smoking 10 cigarettes or more.

          -  Pregnancy or lactating females. Females of childbearing age who are not surgically
             sterilized and are using effective contraception may enter only if an exclusionary
             pregnancy test is done within 72 hours of the first double-blind dose of test agent.
             Pregnancy tests will then be done monthly throughout the study.

          -  Vasculitis or vasculopathy: collagen-vascular diseases, chronic hepatitis B
             antigenemia, circulating immune complexes, complement disorders, amyloidosis,
             scleroderma, etc. Neoplasms, Acquired Immunodeficiency Syndrome (AIDS), or HIV
             positive

          -  Bleeding or platelet disorder

          -  Known absence of one kidney

          -  Subjects abusing or who within past two years abused alcohol or other drug substances

          -  Mentally or legally incapacitated subjects

          -  Subjects who have participated in another investigational drug trial, including those
             using marketed drugs (i.e. patient has signed a consent form), within the 28 days
             prior to start of placebo therapy

          -  Subjects who, in the opinion of the investigator, will not cooperate fully, keep
             appointments or are unreliable

          -  Inability or unwillingness to sign the Patient Consent Form

          -  Phase V of Korotkoff sounds cannot be detected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernesto L. Schiffrin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician-Chief, SMBD - Jewish General Hospital &amp; Professor of Medicine, McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Prevention Centre, Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.jgh.ca</url>
    <description>Sir Mortimer B. Davis - Jewish General Hospital and Lady Davis Institute for Medical Research</description>
  </link>
  <reference>
    <citation>Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000 Apr 11;101(14):1653-9.</citation>
    <PMID>10758046</PMID>
  </reference>
  <reference>
    <citation>Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):40-5. Erratum in: J Renin Angiotensin Aldosterone Syst 2000 Jun;1(2):124.</citation>
    <PMID>11967798</PMID>
  </reference>
  <reference>
    <citation>Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002 Jan;20(1):71-8.</citation>
    <PMID>11791028</PMID>
  </reference>
  <reference>
    <citation>Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, Schiffrin EL. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006 Aug;48(2):271-7. Epub 2006 Jun 19.</citation>
    <PMID>16785331</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2006</study_first_submitted>
  <study_first_submitted_qc>October 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2006</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Ernesto L. Schiffrin</investigator_full_name>
    <investigator_title>Physician-in-Chief</investigator_title>
  </responsible_party>
  <keyword>Remodeling</keyword>
  <keyword>Resistance arteries</keyword>
  <keyword>angiotensin receptor blocker</keyword>
  <keyword>thiazide diuretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

